Document Type : Preliminary preprint short reports of original research
Authors
1
Departments of internal medicine, Hematology, Faculty of Medicine, University of Alexandria, Egypt
2
department of internal medicine hematology unit
3
Clinical Pathology Department, Faculty of Medicine; Alexandria University, Egypt.
4
Department of Internal Medicine, Hematology Unit, Faculty of Medicine, Alexandria University
Abstract
Acute myeloid leukaemia (AML) is a malignant disease that results from the infiltration of immature myelogenous cells into the blood, bone marrow, and other organs, eventually leading to ineffective haematopoiesis and bone marrow failure. The diagnosis of AML typically requires the presence of 20% myeloid blast cells in the bone marrow. However, in cases where AML-defining genetic abnormalities (e.g., t(8;21), inv(16), t(15;17), etc.) are present, the diagnosis can be made regardless of the blast percentage. Management of AML focuses on supportive treatments such as transfusion support, antibiotics, prevention and management of tumor lysis syndrome, and chemotherapy. T lymphocytes and NK cells are well known to provide an immune response against leukaemia cells.
Aim of the work:
The aim of this study was to assess the impact of NK cells and the CD4/CD8 ratio on induction chemotherapy in patients with newly diagnosed AML.
Method:
A sample of 30 patients with de novo AML, eligible for standard induction chemotherapy at Alexandria Main University Hospital, Hematology Unit, were included in this study. Peripheral blood samples were collected before starting chemotherapy, and immunophenotyping was performed to determine the proportion of CD4, CD8, and NK cells. Subsequently, the absolute count of CD4, CD8, and NK cells was obtained based on the CBC of the same samples. We compared the results with those from 15 age- and sex-matched healthy controls.
Keywords
)
View on SCiNiTO